Robert Andtbacka (@robertandtbacka) 's Twitter Profile
Robert Andtbacka

@robertandtbacka

ID: 3140586732

calendar_today05-04-2015 18:36:24

13 Tweet

102 Followers

111 Following

Robert Andtbacka (@robertandtbacka) 's Twitter Profile Photo

Seven and Eight Biopharmaceuticals Inc. reaches important milestone with clinical collaboration with Merck (MSD). The safety and anti tumor activity of BDB001, a novel TLR 7/8 agonist, will be studied in combo with pembrolizumab in pts with solid tumors.businesswire.com/news/home/2019…

Robert Andtbacka (@robertandtbacka) 's Twitter Profile Photo

Just released New Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST ascopubs.org/doi/full/10.12…. Greg Goldmacher Anuradha Khilnani, MD 🇺🇸❤️ Jason Luke, MD, FACPDavid C. Madoff, MD⁩ #itRECIST #oncology #intratumoral #Immunotherapy ascopubs.org/doi/full/10.12…

7and8biopharma (@7and8biopharma) 's Twitter Profile Photo

We are happy to announce an abstract detailing interim data for BDB001 in combination with pembrolizumab was accepted for a poster discussion presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. 7and8biopharma.com/seven-and-eigh…

We are happy to announce an abstract detailing interim data for BDB001 in combination with pembrolizumab was accepted for a poster discussion presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. 7and8biopharma.com/seven-and-eigh…
7and8biopharma (@7and8biopharma) 's Twitter Profile Photo

7and8biopharma reaches a new clinical development milestone for BDB001 monotherapy: First Patient Treated in a Phase 2 Clinical Trial in anti-PD-1 / anti-PD-L1 Refractory Solid Tumors. Full Release: 7and8biopharma.com/seven-and-eigh… #immunotherapy #cancer #oncology #TLR78 #BDB001

<a href="/7and8biopharma/">7and8biopharma</a> reaches a new clinical development milestone for BDB001 monotherapy: First Patient Treated in a Phase 2 Clinical Trial in anti-PD-1 / anti-PD-L1 Refractory Solid Tumors.

Full Release: 7and8biopharma.com/seven-and-eigh…
#immunotherapy #cancer #oncology #TLR78  #BDB001
Robert Andtbacka (@robertandtbacka) 's Twitter Profile Photo

I am thrilled to join the #HiFiBiO team as Chief Medical Officer. I am deeply impressed by HiFiBiO’s innovative approach to developing novel #immune therapies. Together we will advance groundbreaking therapies, providing improved disease treatments and renewed hope for #patients.